跳至主要内容
临床试验/NCT04558164
NCT04558164进行中(未招募)不适用

Network-targeted Theta-burst Stimulation for Episodic Memory Improvement in Mild Cognitive Impairment

University of California, Los Angeles1 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2021年1月26日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
70
试验地点
1
主要终点
Object recognition memory performance change

研究概览

简要总结

The purpose of this study is to see if stimulation of the brain can improve memory. The investigators will use a device called transcranial magnetic stimulation that can stimulate and activate a specific part of the brain that is important for memory. The study will enroll MCI subjects and subjects with subjective memory complaints who will be randomly assigned to receive active or sham brain stimulation. 'Blinded' or 'sham-controlled' means that the subject will not know whether the treatment they receive is the active treatment or the non-active stimulation. In the 'sham' condition, the stimulator will turn on but will not actually be stimulating the target brain region.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Participant)

入排标准

年龄范围
55 Years 至 100 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Agreement to participate in the study
  • •55-100 years of age
  • •Right-handedness
  • •In good general health
  • •Living independently
  • •Subjective memory complaints (self-report and positive score on MFQ)
  • •Katz ADL scale and Lawton iADL scale: We will review scores on a case-by-case basis if they did not score 100%. We will exclude if the scores show impairment in ADLs that suggests problems with independent functioning due to cognitive impairment.
  • •MMSE score > 24
  • •PHQ Depression score =< 7
  • •Ability to read, write, and speak English fluently
  • •Diagnosis of mild neurocognitive disorder according to DSM-5 (Diagnostic and Statistical Manual of Mental Disorders) criteria. Participants with subjective memory complaints without an aMCI diagnosis will be reviewed on a case-by-case basis based on neuropsychological scores. Participants scoring a raw score of 0 or 3 standard deviations below normative expectations on the long delay recall in two or more of the three tasks (BVMT-R, RCFT, and CVLT-III) will be excluded.
  • •No change in use of psychotropic medication for treatment of depression, anxiety, ADHS or psychosis 1 month prior and during the study.
  • •Screening diagnostic criteria for aMCI will be subjective memory complaints, intact instrumental and basic activities of daily living (Smith et al., 1996), PHQ, MMSE, BVMT-R (25-minute delay), CVLT-II (20-minute delay), Rey-Osterrieth Complex Figure Task (30-minute delay). Baseline assessments will include neuropsychological testing of all study subjects.

排除标准

  • •Unwilling or unable to provide informed consent
  • •Diagnosis of dementia
  • •Active major medical, psychiatric, or neurologic disorder associated with neurocognitive impairment
  • •History of alcohol or substance abuse
  • •Recent (< 6 months) alcohol or substance abuse (excluding nicotine or caffeine)
  • •History of stroke (if the stroke in our judgment is related to the memory problem), traumatic brain injury with loss of consciousness, or other neurologic disorder (e.g., epilepsy, Huntington's disease, Parkinson's disease)
  • •Non-English speaking participants
  • •Not right handed based on self-report or evaluation based on a standard report
  • •Has received TMS before (not TMS naïve)
  • •Poorly controlled hypertension or cardiovascular disease
  • •Current enrollment in a memory-enhancement study or course
  • •Contraindication to TMS or MRI including claustrophobia, metal in body, surgery within 60 days, certain implants, or previous abnormal MRI results.
  • •scanning facial tattoos is okay if safe with MRI
  • •is taking:
  • •anticholinergic medication (e.g., Detrol, Cogentin);
  • •sedating antihistamine (e.g., Benadryl);
  • •any drug that has significant anticholinergic or antihistaminic side effects (e.g., tricyclic antidepressant medications, Remeron).
  • •benzodiazepines. While not a strict rule out, this will be decided on a case-by-case basis depending on the dose.

研究组 & 干预措施

Active TBS

Experimental

Theta burst stimulation (TBS) will be delivered at 100% of motor threshold (MT).

干预措施: Active Theta Burst Stimulation (Device)

Sham TBS

Sham Comparator

Sham stimulation will be delivered at 0% of motor threshold (MT), with all other parameters matching the active TBS condition.

干预措施: Sham Theta Burst Stimulation (Device)

结局指标

主要结局

Object recognition memory performance change

时间窗: Baseline: Day 2; During stimulation: Day 3, Day 7, Day 12, Day 17; Follow-up appointments: Day 18, Day 19, Day 20.

Object memory will be measured using an recognition task where participants view photos of everyday objects and are asked to identify them as OLD or NEW during a memory test wherein unseen novel objects and very similar but new photos of identical objects are shown. Recollection and discrimination index will be used to quantify memory performance changes.

Verbal recall performance change

时间窗: Baseline: Day 2; During stimulation: Day 3, Day 7, Day 12, Day 17; Follow-up appointments: Day 18, Day 19, Day 20.

Verbal memory will be measured using a free recall task where participants learn a list of everyday words and are asked to recall as many words as they can remember after a period of distraction. Proportion of recollected words will be used to quantify memory performance changes.

Associative memory performance change

时间窗: Baseline: Day 2; During stimulation: Day 3, Day 7, Day 12, Day 17; Follow-up appointments: Day 18, Day 19, Day 20.

Associative memory will be tested using the Face Name Memory Test wherein participants are shown faces and associated names. Participants are then shown faces only and asked to recall the associated name.

次要结局

  • EEG activity(During treatment (Days 3, 7 and 12), after the last treatment (Day 17), and 2 month follow-up session (Day 20))
  • Resting state fMRI functional connectivity(Baseline (Day 2) before the first treatment and after the last treatment (Day 17))

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Andrew F. Leuchter

Principal Investigator

University of California, Los Angeles

研究点 (1)

Loading locations...

相似试验